MeiraGTx Holdings stock (US58550P1012): gene therapy developer trades around 9 USD after recent volatility

MeiraGTx Holdings shares on Nasdaq have been fluctuating around the high single digits in recent sessions as investors weigh the company’s late-stage gene therapy pipeline and recent regulatory milestones in the United States.

MeiraGTx Holdings shares continue to change hands on the Nasdaq in the high single-digit range as investors react to the company’s progress in late-stage gene therapy programs and recent U.S. regulatory designations.

According to Invezz, MeiraGTx Holdings traded at about USD 9.57 in early June 2026 on Nasdaq under the ticker MGTX, after a period of notable volatility in previous sessions.Invezz as of 06/2026

MarketBeat reported that MeiraGTx stock was quoted at around USD 9.07 during intraday trading in early June 2026, illustrating how the share price has been oscillating within a relatively narrow band over recent days.MarketBeat as of 06/2026

The United States remains the company’s primary market, with MeiraGTx listed on the Nasdaq, and regulatory developments from the U.S. Food and Drug Administration are a key driver of sentiment around the stock.

For German investors, the stock is also accessible on local trading venues such as Tradegate, where it typically trades in euros and tracks the U.S. primary listing in terms of direction, although local liquidity and spreads can differ from the home exchange.

As of: 06/05/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: MGTX
• Sector/industry: Genetic medicines / biotechnology
• Headquarters/country: London, United Kingdom
• Core markets: United States, Europe
• Key revenue drivers: Gene therapy candidates and collaboration income
• Home exchange/listing venue: Nasdaq (MGTX)
• Trading currency: USD

MeiraGTx Holdings: core business model

MeiraGTx Holdings focuses on developing gene-based therapies for serious diseases, with value creation tied mainly to advancing its clinical-stage genetic medicine programs and partnering or licensing opportunities.

Valuation metrics and multiples for MeiraGTx Holdings

As a clinical-stage biotechnology company without approved commercial products, MeiraGTx is typically valued by investors on the basis of its pipeline progress and future potential cash flows rather than traditional earnings-based metrics.

Public market data providers indicate that, at a share price in the area of USD 9 to USD 10 in early June 2026, MeiraGTx’s equity value is in the several-hundred-million-dollar range, reflecting expectations for its late-stage gene therapy assets despite the absence of recurring product revenue at this stage.StockTitan as of 06/2026

Given the lack of positive net earnings, common valuation ratios such as price-to-earnings are not meaningful, and many investors instead monitor enterprise value relative to research and development spending and to the perceived risk-adjusted sales potential of the company’s lead programs.

In this context, movements in MeiraGTx’s market capitalization can be closely tied to clinical trial readouts, regulatory designations, and any updates on potential commercial partnerships that might bring in upfront payments or milestone-based funding.

Conclusion

MeiraGTx Holdings’ stock is currently trading on Nasdaq in the high single-digit dollar range, with recent quotes around USD 9.57 and USD 9.07 illustrating an active but contained trading range as of early June 2026.

With conventional valuation metrics limited by the lack of commercialized products, investors are likely to focus on how upcoming clinical and regulatory milestones may alter expectations for the company’s future cash flows and, in turn, its market capitalization.

Against this backdrop, MeiraGTx remains a clinical-stage gene therapy name where sentiment can shift quickly in response to newsflow, and where understanding the company’s pipeline and valuation framework is central to interpreting the stock’s movements.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.